InvestorsHub Logo
Followers 8
Posts 1912
Boards Moderated 0
Alias Born 09/10/2012

Re: None

Wednesday, 06/29/2022 7:39:37 AM

Wednesday, June 29, 2022 7:39:37 AM

Post# of 660
Brokerage believes Sunosi has potential to become a mainstay as first-line non-generic therapeutic in these indications; assumes peak market penetration of 14%
Cantor Fitzgerald raises PT for drug developer Axsome Therapeutics (AXSM.O) to $64 from $47 on growth potential of its newly acquired drug Sunosi
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AXSM News